Highlights
- 1Blood cancer discovery · 2023
- 2Blood · 2020
- 3Blood advances · 2020
Publications
75 publications
Funding
28 grantsView NIH portfolio on RePORTER ↗
Active
15 grants- KPHHWF 240412-01Biomarkers of response in primary mediastinal B-cell lymphoma: Defining tumor microenvironment signaturesHyundai Hope on Wheels Foundation · 2024–2026
- KPPF-23-1143526-01-IBCDTargeting latency switch for the treatment of EBV-associated lymphomasAmerican Cancer Society · 2024–2026
- Sub-PIW81XWH-22-1-0665Assessment of Clonal Hematopoiesis and Its Relationship to Cardiovascular Disease in Hodgkin Lymphoma SurvivorsU.S. Department of Defense · 2022–2026 · via Washington University, The
- MPIASH 250160-01Sensitizing Latency I EBV Lymphomas to Cytotoxic T Lymphocyte TherapyAmerican Society of Hematology Inc · 2025–2026
- KPLRF 244461-01Sensitizing Latency I EBV Lymphomas to Cytotoxic T Lymphocyte TherapyLymphoma Research Foundation · 2025–2026
- Sub-PIW81XWH-22-1-0338An Integrative Radiogenomic Framework for Predicting Treatment Failure in Adolescents & Young Adults with Hodgkin LymphomaU.S. Department of Defense · 2022–2026 · via Emory University
- MPIUG1CA233249-06Targeting CD30 to enhance response to immune checkpoint blockade in Hodgkin LymphomaNational Cancer Institute · 2022–2026 · via Children's Oncology Group· 3 renewals
- Sub-PI5 UG1 CA233249- 06A pilot study to evaluate ctDNA in PMBCLNational Cancer Institute · 2025–2026 · via Children's Oncology Group
- Sub-PINY018_2024_01_ROTHCOG Hodgkin Lymphoma (Defining Biomarkers of Response to Immunotherapy in Pediatric Hodgkin Lymphoma - The Jeffrey Pride Foundation Integrated Correlative Biology Awards)Jeffrey Pride Foundation INC · 2024–2026 · via Children's Oncology Group
- Sub-PI5 UG1 CA233249- 06Evaluating Biologic Mechanisms of Racial and Ethnic Disparities in Pediatric Hodgkin LymphomaNational Cancer Institute · 2024–2026 · via Children's Oncology Group
- Sub-PI5 UG1 CA233249- 06Overcoming resistance to PD-1 Blockade in Hodgkin LymphomaNational Cancer Institute · 2024–2026 · via Children's Oncology Group
- MPICOG 222649-02Risk Stratification using Tumor Microenviroment Signatures in Hodgkin LymphomaChildren's Oncology Group · 2022–2026
- MPIU10CA180886-11COG U10CA180886 PO: 0000004866National Cancer Institute · 2020–2026 · via Public Health Institute· 3 renewals
Completed grants (13)
- PICOG 222665-01Biomarkers Predictive of Antitumor Response in Primary Mediastinal B-cell LymphomaChildren's Oncology Group · 2022–2025
- Sub-PISA 203887-01AHO1822 Study ChairMerck & Co., Inc. · 2020–2025 · via The Children’s Hospital of PhiladelphiaContract
- Sub-PINY018_2024_02_ROTHGenomic and Immunologic Predictors of Response in Primary Mediastinal B-cell Lymphoma - The Jeffrey Pride Foundation Integrated Correlative Biology AwardsJeffrey Pride Foundation INC · 2024–2025 · via Children's Oncology Group
- PISCC I15-0016Defining the evolution and tumor microenvironment interactions of classic Hodgkin lymphoma through single-cell multi-omics and genetically engineered mouse modelsStarr Cancer Consortium · 2022–2024
- PIHHWF 215201-02Targeting latent viral antigens in EBV+ Burkitt LymphomaHyundai Hope on Wheels Foundation · 2021–2024
- PIASH 210413-02Modulation Of Viral Latency In EBV+ Lymphomas To Sensitize Tumors To ImmunotherapyAmerican Society of Hematology Inc · 2021–2023
- PIK08CA219473-04Rational Translation of EZH2 Targeted Therapy in Germinal Center B-Cell LymphomaNational Cancer Institute · 2017–2021Career
- PITHF 190511-01Why Personalized Medicine Fails: Shifting Focus to Genotype the Rare Cancer-initiating Cell in Hodgkin LymphomaThe Hartwell Foundation · 2019–2021
- PII11-0043Modulation of Viral Latency in EBV-Associated Lymphomas as a Mechanism to Sensitize Tumors to EBV-Directed Cellular TherapyStarr Cancer Consortium · 2018–2020
- PICOG 191520-01Whole exome and RNA sequencing of Hodgkin Reed-Sternberg cells isolated from pediatric Hodgkin lymphoma cases across COG sitesChildren's Oncology Group · 2019–2019
- PISBF 170821-03Targeting the Hsp90 Oncoproteome in Pediatric Burkitt LymphomaSt. Baldrick's Foundation · 2015–2018
- MPIU01CA121947-04 EWAMC Fellowship ProgramNational Cancer Institute · 2014–2015 · via University of California, Los Angeles
- MPIP30CA008748-49 EWGenomic Biomarker Discovery in AIDS-Related Burkitt LymphomaNational Cancer Institute · 2014–2015 · via Sloan-Kettering Institute for Cancer Research
Honors & distinctions
1 honor
- Member · American Society for Clinical Investigation · 2023
Clinical research
4 studies
Active
2 studies- PIBody Mass Index and the Development of Subsequent Malignant Neoplasms among Adolescent and Young Adult Cancer SurvivorsWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
- PIRetrospective multi-center study evaluating the benefit of consolidation with brentuximab vedotin following autologous stem cell transplant in pediatric patients with relapsed/refractory Hodgkin lymphomaMemorial Sloan Kettering Cancer Center · OPEN TO ACCRUAL (as of 2021)
Completed & closed trials (2)
- PICITY OF HOPE: A multicenter retrospective study of pediatric patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)City of Hope National Medical Center · CLOSED TO ACCRUAL (as of 2025)
- PINCT03407144An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)PHASE2 · Children's Oncology Group · IRB STUDY CLOSURE (as of 2023)Hodgkin Lymphoma
Available technologies
1 technologyView full WCM portfolio ↗
- Epigenetic Modifying Agents Sensitize EBV+ Lymphomas to ImmunotherapyApplication filedPoC DataPMID 32157281
News mentions
2 mentionsView all WCM news ↗
- Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better DiagnosticsApril 24, 2026
For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an “identity crisis.”
- Record Number of Weill Cornell Faculty Win ASCI Young Physician-Scientist AwardsMay 27, 2021
Eight Weill Cornell Medicine faculty members have received Young Physician-Scientist Awards from the American Society for Clinical Investigation (ASCI), the most awarded to any institution this year.
Mentoring
1 menteeAll publications with mentees →
- KWKyle WierzbickiMD mentee · Class of 2025
External relationships
Other Interest
Gerson Lehrman Group (GLG) · Guidepoint Global LLC · Roche Pharmaceuticals, Inc. · Rosenblum Newfield, LLC
Other
Roche Pharmaceuticals, Inc.